With a portfolio currently comprised of 45 commercial products and five developmental-stage candidates in various areas, including rare disease and neurology, the company featured in today’s article is in the unique business of buying biopharmaceutical royalties. However, after an impressive debut in June 2020, its shares have fluctuated markedly since. Is this unique stock worth buying right now? For a look at the factors that could influence its performance in the coming months, CLICK HERE.
Is This Biopharma Company With A Unique Business A Buy?
- by davidgoldstein
- March 29, 2021April 17, 2021